Nervous about needles? FDA OKs Janssen injection device for the squeamish

The Food and Drug Administration on Wednesday granted marketing approval to Janssen Pharmaceutical Co.'s Tremfya One-Press, a patient-controlled injector designed for people with moderate-to-severe psoriasis. Tremfya is Horsham-based Janssen Biotech's biologic treatment approved by the FDA in 2017 for psoriasis, a chronic inflammatory disorder that results in the overproduction of skin cells. The condition causes raised, inflamed, red lesions or plaques — which can result in physical pain and…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news